HC Wainwright & Co. Reiterates Buy on Maze Therapeutics, Maintains $110 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 90.8%

Neg 0% Neu 90.8% Pos 0%

HC Wainwright & Co. analyst Ananda Ghosh reiterates Maze Therapeutics (NASDAQ:MAZE) with a Buy and maintains $110 price target.